Protection against 12-O-tetradecanoylphorbol-13-acetate induced skin-hyperplasia and tumor promotion, in a two-stage carcinogenesis mouse model, by the 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-[2,3-b]quinoxaline analogue of ellipticine

Chemico-Biological Interactions

Volumn 122, Issue 2, 1999, Pages 89-106

  Skarin, Tobias ^a   Lundh Rozell, Barbro ^b   Bergman, Jan ^a   Toftgård, Rune ^a   Möller, Lennart ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti carcinogen; Benzoyl peroxide; Ellipticine analogue; Mouse skin; Oxidative stress; Tumor promotion

Indexed keywords

2,3 DIMETHYL 6 (2 DIMETHYLAMINOETHYL) 6H INDOLO[2,3 B]QUINOXALINE; BENZOYL PEROXIDE; ELLIPTICINE; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; EPIDERMIS HYPERPLASIA; FEMALE; INFLAMMATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION; TUMOR PROMOTION;

EID: 0032829688     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(99)00117-9     Document Type: Article

References (54)

1. Yuspa S.H., Dlugosz A.A., Denning M.F., Glick A.B. Multistage carcinogenesis in the skin. J. Invest. Dermatol. Symp. Proc. 1:1996;147-150.
2. Parkinson E.K. Defective responses of transformed keratinocytes to terminal differentiation stimuli. Their role in epidermal tumour promotion by phorbol esters and by deep skin wounding. Br. J. Cancer. 52:1985;479-493.
3. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol. Ther. 54:1992;63-128.
4. Loehrke H., Schweizer J., Dederer E., Hesse B., Rosenkranz G., Goerttler K. On the persistence of tumor initiation in two-stage carcinogenesis on mouse skin. Carcinogenesis. 4:1983;771-775.
5. Stenbäck F., Peto R., Shubik P. Initiation and promotion at different ages and doses in 2200 mice. II. Decrease in promotion by TPA with ageing. Br. J. Cancer. 44:1981;15-23.
6. Stenbäck F., Peto R., Shubik P. Initiation and promotion at different ages and doses in 2200 mice. I. Methods, and the apparent persistence of initiated cells. Br. J. Cancer. 44:1981;1-14.
7. Raick A.N. Ultrastructural, histological, and biochemical alterations produced by 12-O-tetradecanoyl-phorbol-13-acetate on mouse epidermis and their relevance to skin tumor promotion. Cancer Res. 33:1973;269-286.
8. Raick A.N. Late ultrastructural changes induced by 12-O-tetradecanoyl-phorbol-13-acetate in mouse epidermis and their reversal. Cancer Res. 33:1973;1096-1103.
9. Lewis J.G., Adams D.O. Early inflammatory changes in the skin of SENCAR and C57BL/6 mice following exposure to 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis. 8:1987;889-898.
10. Athar M., Lloyd J.R., Bickers D.R., Mukhtar H. Malignant conversion of UV radiation and chemically induced mouse skin benign tumors by free-radical-generating compounds. Carcinogenesis. 10:1989;1841-1845.
11. Binder R.L., Aardema M.J., Thompson E.D. Benzoyl peroxide: review of experimental carcinogenesis and human safety data. Prog. Clin. Biol. Res. 391:1995;245-294.
12. Boutwell R.K. The biochemistry of preneoplasia in mouse skin. Cancer Res. 36:1976;2631-2635.
13. Slaga T.J., Bowden G.T., Boutwell R.K. Acetic acid, a potent stimulator of mouse epidermal macromolecular synthesis and hyperplasia but with weak tumor-promoting ability. J. Natl. Cancer Inst. 55:1975;983-987.
14. Slaga T.J., Scribner J.D., Viaje A. Epidermal cell proliferation and promoting ability of phorbol esters. J. Natl. Cancer Inst. 57:1976;1145-1149.
15. Klein-Szanto A.J., Slaga T.J. Effects of peroxides on rodent skin: epidermal hyperplasia and tumor promotion. J. Invest. Dermatol. 79:1982;30-34.
16. Slaga T.J., Klein-Szanto A.J., Triplett L.L., Yotti L.P., Trosko K.E. Skin tumor-promoting activity of benzoyl peroxide, a widely used free radical-generating compound. Science. 213:1981;1023-1025.
17. Huang M.T., Ho C.T., Wang Z.Y., Ferraro T., Finnegan-Olive T., Lou Y.R., Mitchell J.M., Laskin J.D., Newmark H., Yang C.S., Conney A.H. Inhibitory effect of topical application of a green tea polyphenol fraction on tumor initiation and promotion in mouse skin. Carcinogenesis. 13:1992;947-954.
18. Chen L.C., Sly L., Jones C.S., Tarone R., De Luca L.M. Differential effects of dietary beta-carotene on papilloma and carcinoma formation induced by an initiation-promotion protocol in SENCAR mouse skin. Carcinogenesis. 14:1993;713-717.
19. Wei H., Tye L., Bresnick E., Birt D.F. Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res. 50:1990;499-502.
20. Agarwal R., Katiyar S.K., Lundgren D.W., Mukhtar H. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis. 15:1994;1099-1103.
21. Kandaswami C., Middleton Jr E. Free radical scavenging and antioxidant activity of plant flavonoids. Adv. Exp. Med. Biol. 366:1994;351-376.
22. Lepley D.M., Li B., Birt D.F., Pelling J.C. The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis. 17:1996;2367-2375.
23. Lepley D.M., Pelling J.C. Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol. Carcinog. 19:1997;74-82.
24. Goodwin S., Smith A.F., Horning E.C. Alkaloids of Ochrosia elliptica Labill. J. Am. Chem. Soc. 81:1958;1903-1908.
25. Dalton L.K., Demerac S., Elmes B.C., Loder J.C., Swan J.M., Teitei T. Synthesis of the tumour-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido(4,3-b)carbazoles. Aust. J. Chem. 20:1967;2715-2727.
26. Alworth W.L., Slaga T.J. Effects of ellipticine, flavone, and 7,8-benzoflavone upon 7,12-dimethylbenz[a]anthracene, 7,14-dimethyldibenzo[a,h]anthracene and dibenzo[a,h]anthracene initiated skin tumors in mice. Carcinogenesis. 6:1985;487-493.
27. Paoletti C., Cros S., Xuong N.D., Lecointe P., Moisand A. Comparative cytotoxic and antitumoral effects of ellipticine derivatives on mouse L 1210 leukemia. Chem. Biol. Interact. 25:1979;45-58.
28. Delbarre A., Oberlin R., Roques B.P., Borgna J.L., Rochefort H., Le Pecq J.B., Jacquemin-Sablon A. Ellipticine derivatives with an affinity to the estrogen receptor, an approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer. J. Med. Chem. 28:1985;752-761.
29. Samadi-Baboli M., Favre G., Blancy E., Soula G. Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro. Eur. J. Cancer Clin. Oncol. 25:1989;233-241.
30. Alberici G.F., Pallardy M., Manil L., Dessaux J.J., Fournier J., Mondesir J.M., Bohuon C., Gros P. Conjugates of elliptinium acetate with mouse monoclonal anti-alpha-fetoprotein antibodies or Fab fragments: in vitro cytotoxic effects upon human hepatoma cell lines. Int. J. Cancer. 41:1988;309-314.
31. Juret P., Tanguy A., Girard A., Le Talaer J.Y., Abbatucci J.S., Dat-Xuong N., Le Pecq J.B., Paoletti C. Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264 - 137) in advanced human cancers. Eur. J. Cancer. 14:1978;205-206.
32. Paoletti C., Le Pecq J.B., Dat-Xuong N., Juret P., Garnier H., Amiel J.L., Rouesse J. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium. Recent Results in Cancer Res. 74:1980;107-123.
33. Kohn K.W., Waring M.J., Glaubiger D., Friedman C.A. Intercalative binding of ellipticine to DNA. Cancer Res. 35:1975;71-76.
34. Multon E., Riou J.F., LeFevre D., Ahomadegbe J.C., Riou G. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417. Biochem. Pharmacol. 38:1989;2077-2086.
35. Ferlin M.G., Chiarelotto G., Marzano C., Mobilio S., Carlassare F., Baccichetti F. Antiproliferative activity of some unsubstituted angular analogoues of ellipticine. Farmaco. 50:1995;91-98.
36. Lesca P., Mansuy D. 9-Hydroxyellipticine: inhibitory effect on skin carcinogenesis induced in Swiss mice by 7,12-dimethylbenz[a]anthracene. Chem. Biol. Interact. 30:1980;181-187.
37. Zegar I., Gräslund A., Bergman J., Eriksson M., Norden B. Interaction of ellipticine and an indolo[2,3b]-quinoxaline derivative with DNA and synthetic polynucleotides. Chem. Biol. Interact. 72:1989;277-293.
38. Patel N., Bergman J., Gräslund A. 1H-NMR studies of the interaction between a self-complementary deoxyoligonucleotide duplex and indolo[2,3-b]quinoxaline derivatives active against herpes virus. Eur. J. Biochem. 197:1991;597-604.
39. Harmenberg J., Wahren B., Bergman J., Åkerfeldt S., Lundblad L. Antiherpesvirus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogs. Antimicrob. Agents Chemother. 32:1988;1720-1724.
40. Sehlstedt U., Aich P., Bergman J., Vallberg H., Norden B., Gräslund A. Interactions of the antiviral quinoxaline derivative 9-OH-B220 [2, 3-dimethyl-6-(dimethylaminoethyl)- 9-hydroxy-6H-indolo-[2, 3-b]quinoxaline] with duplex and triplex forms of synthetic DNA and RNA. J. Mol. Biol. 278:1998;31-56.
41. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:1992;493-501.
42. Kane K.S., Maytin E.V. Ultraviolet B-induced apoptosis of keratinocytes in murine skin is reduced by mild local hyperthermia. J. Invest. Dermatol. 104:1995;62-67.
43. Verma A.K. Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment. Cancer Res. 47:1987;5097-5101.
44. Katiyar S.K., Agarwal R., Ekker S., Wood G.S., Mukhtar H. Protection against 12-O-tetradecanoylphorbol-13-acetate-caused inflammation in SENCAR mouse ear skin by polyphenolic fraction isolated from green tea. Carcinogenesis. 14:1993;361-365.
45. Lesca P., Lecointe P., Paoletti C., Mansuy D. Ellipticines as potent inhibitors of aryl hydrocarbon hydroxylase: their binding to microsomal cytochromes P450 and protective effect against benzo(a)pyrene mutagenicity. Biochem. Pharmacol. 27:1978;1203-1209.
46. Ohashi M., Sugikawa E., Nakanishi N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn. J. Cancer Res. 86:1995;819-827.
47. Aldaz C.M., Conti C.J., Chen A., Bianchi A., Walker S.B., DiGiovanni J. Promoter independence as a feature of most skin papillomas in SENCAR mice. Cancer Res. 51:1991;1045-1050.
48. Ewing M.W., Conti C.J., Kruszewski F.H., Slaga T.J., DiGiovanni J. Tumor progression in Sencar mouse skin as a function of initiator dose and promoter dose, duration, and type. Cancer Res. 48:1988;7048-7054.
49. O. Harbecke, C. Dahlgren, J. Bergman, L. Möller, The synthetic non-toxic drug 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2, 3-b)quinoxaline inhibits neutrophil production of reactive oxygen species, J. Leukocyte Biol. (1999) in press.
50. Nishizuka Y. Studies and prospectives of the protein kinase c family for cellular regulation. Cancer. 63:1989;1892-1903.
51. Blumberg P.M. Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res. 48:1988;1-8.
52. Leach K.L., Blumberg P.M. Modulation of protein kinase C activity and [3H]phorbol 12,13-dibutyrate binding by various tumor promoters in mouse brain cytosol. Cancer Res. 45:1985;1958-1963.
53. Mintz E., Wang N., DeLeo V.A., Matsui M.S. Benzoyl peroxide modulation of protein kinase C in cultured human epidermal keratinocytes. J. Invest. Dermatol. 98:1992;635.
54. Kensler T.W., Egner P.A., Moore K.G., Taffe B.G., Twerdok L.E., Trush M.A. Role of inflammatory cells in the metabolic activation of polycyclic aromatic hydrocarbons in mouse skin. Toxicol. Appl. Pharmacol. 90:1987;337-346.